Article
Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson's disease-like phenotype.
Molecular therapy : the journal of the American Society of Gene Therapy - 6 Apr 2022
Faustini Gaia, Longhena Francesca, Masato Anna, Bassareo Valentina, Frau Roberto, Klingstedt Therése, Shirani Hamid, Brembati Viviana, Parrella Edoardo, Vezzoli Marika, Nilsson K Peter R, Pizzi Marina, Spillantini Maria Grazia, Bubacco Luigi, Bellucci Arianna
Abstract excerpt
Fibrillary aggregated α-synuclein (α-syn) deposition in Lewy bodies (LB) characterizes Parkinson's disease (PD) and is believed to trigger dopaminergic synaptic failure and a retrograde terminal-to-cell body neuronal degeneration. We described that the neuronal phosphoprotein synapsin III (Syn III) cooperates with α-syn to regulate dopamine (DA) release and can be found in the insoluble α-syn fibrils composing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.